StopDown
PharmEasy logo
Stake sale · 16 August 2026PharmEasyOnline pharmacy and diagnosticspharmeasy.in ↗

API Holdings sells Thyrocare stake, repays debt

By · Editor ·

Navi MumbaiFounded 2019
  • API Holdings runs PharmEasy, an online pharmacy, and Thyrocare, a diagnostics chain
  • Its subsidiary Docon sold 9.9% of Thyrocare for ₹986 crore, used to repay ₹1,050 crore debt
  • The company is now debt-free and expects PharmEasy to turn profitable within 3-4 quarters

What happened

  • API Holdings, the parent of PharmEasy and Thyrocare, repaid ₹1,050 crore of debt and became debt-free.
  • Its subsidiary Docon Technologies sold 1.57 crore Thyrocare shares (9.9% stake) on 13 August 2026 for ~₹986 crore.
  • The block deal was executed at ₹624 per share, a ~3% discount to the previous close.
  • Buyers included Citigroup, Morgan Stanley, and HSBC Mutual Fund.
  • Thyrocare stock fell ~8% intraday on 13 August after the stake sale.
  • Earlier, Docon sold ~10% of Thyrocare in October 2025 for ~₹668 crore.
  • The two stake sales together raised ~₹1,650 crore for API Holdings.
  • After the sale, promoter holding in Thyrocare dropped from 60.92% to 51.02%.

Why it matters

  • API Holdings had borrowed ₹2,280 crore from Goldman Sachs in 2022 at 17-18% interest to refinance the Thyrocare acquisition debt.
  • In 2023, it breached a loan covenant after failing to raise ~₹1,000 crore in equity.
  • The debt repayment freed the pledge on 79.5 million Thyrocare shares.

The business

  • API Holdings operates PharmEasy (online pharmacy), Thyrocare (diagnostics), Ascent (medicine distributor), and Aknamed (hospital supply chain).
  • PharmEasy offers medicine delivery, lab tests, doctor consultations, vaccinations, elder care, nursing, and AI-powered physiotherapy.
  • Its AI physiotherapy platform uses smartphone camera for posture analysis and covers 250+ conditions with 60+ physiotherapists.
  • PharmEasy lab tests are powered by Thyrocare.
  • The B2B business (including Ascent) had Q1 FY27 revenue of ₹1,005.6 crore, up 8% YoY.
  • Thyrocare processed 55.2 million tests in Q1 FY27, up 28% YoY.

The founders

Siddharth Shah

Co-founder & Vice Chairman
in
  • Co-founded PharmEasy.
  • Said the biggest mistake was not using available capital to repay debt, instead deploying it for growth and secondary share buyback.

Dharmil Sheth

Co-founder
in
  • Co-founded PharmEasy.

Dr. Dhaval Shah

Co-founder
in
  • Co-founded PharmEasy.

Who put in money

  • Citigroup buyer — Global investment bank.
  • Morgan Stanley buyer — Global financial services firm.
  • HSBC Mutual Fund buyer — Asset management arm of HSBC.
  • Prosus existing — Global consumer internet group and investor.
  • Temasek existing — Singaporean state-owned investment company.
  • TPG Growth existing — Growth equity arm of TPG Capital.
  • CDPQ existing — Canadian pension fund manager.
  • 360 One existing — Indian wealth and asset management firm.
  • Ranjan Pai's MEMG existing — Largest shareholder in API Holdings with estimated stake >12%.

In numbers

₹1,050 croreDebt repaid · 2026
1,57,69,696Thyrocare shares sold · 2026
~₹986 croreSale proceeds · 2026
₹624Sale price per share · 2026
51.02%Promoter holding after sale · 2026
~₹1,650 croreTotal from two stake sales · 2026
₹240 croreThyrocare Q1 FY27 revenue · 2026
₹51 croreThyrocare Q1 FY27 PAT · 2026
₹77 croreThyrocare Q1 FY27 EBITDA · 2026
₹1,754 croreAPI Holdings Q1 FY27 revenue · 2026
₹29.6 croreAPI Holdings Q1 FY27 loss (ex-Esop) · 2026
₹39.3 croreAPI Holdings Q1 FY27 EBITDA · 2026
₹348 crorePharmEasy Q1 FY27 revenue · 2026
₹17 crorePharmEasy Q1 FY27 EBITDA loss · 2026
₹5,980 croreAPI Holdings FY25 revenue · 2025
₹1,572 croreAPI Holdings FY25 net loss · 2025
$5.6 billionPharmEasy valuation 2021
~$700 millionPharmEasy valuation 2024

Earlier rounds

  • 2024 · rights issue · ₹3,500 crore
  • 2025 · debentures · ₹1,700 crore

Up against

Tata 1mgReliance-owned NetmedsApollo 247Fix HealthPhyt.healthFlexifyMePractoMediBuddy

Words to know

Block deal
A large sale of shares arranged privately between a seller and a few buyers, often at a discount to the market price.
Promoter holding
The percentage of a company's shares owned by its founders or founding group.
Pledge
Shares given as collateral for a loan; if the loan is not repaid, the lender can sell the shares.
Reverse merger
A private company merges into a public company, allowing the private company to become publicly traded without an IPO.

The numbers around it

Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Profitability: A path to profitability is the plan and evidence that a startup will earn more than it spends. In India the usual order is contribution positive, then EBITDA positive, then net profit and positive cash flow. Each step is a different test, so claims of profit need the definition.
  • Profitability: Profitable can mean five different things in a startup headline: profit after tax, positive EBITDA, positive adjusted EBITDA, positive cash flow or profit on each order. Only the first is a profit in the full accounting sense. Always check which one a story means.

Everything on PharmEasy → · All startup news on 16 August 2026 →

Is this PharmEasy? Get your “Featured on StopDown” badge →